Hamza Kandoussi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hamza Kandoussi has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Hao Jiang
Bioanalytical Sciences, Bristol-Myers Squibb Co., Princeton, NJ 08543, USA
3 shared publications - Jianing Zeng
Analytical & Bioanalytical Development, Bristol-Myers Squibb Company, Princeton, NJ 08543, USA
3 shared publications Laura Cojocaru
Tandem Laboratory, A LabCorp Division, Trenton, NJ 08628, USA
3 shared publicationsPathanjali Kadiyala
Analytical & Bioanalytical Operations, Bristol-Myers Squibb Company, Princeton, NJ 08543, USA
3 shared publicationsBing He
Early Clinical and Translational Research, Bristol-Myers Squibb Company, Hopewell, NJ 08543, USA
2 shared publicationsJohn Easter
Discovery Chemistry Platforms-Radiochemistry, Bristol-Myers Squibb Company, Princeton, NJ 08543, USA
2 shared publications
Latest Publications
- 11 May 2018
- Published by Taylor & Francis in Bioanalysis
- Vol. 10 (9) , 633-644
UHPLC–MS/MS Bioanalysis of Human Plasma Coproporphyrins as Potential Biomarkers for Organic Anion-Transporting Polypeptide-Mediated Drug Interactions
Aim: Coproporphyrins (CP-I and CP-III) have been identified as possible biomarkers to predict human hepatic organic anion-transporting polypeptides-mediated-drug-interactions for a new drug entering clinical development. Results: The method is applicable to quantify plasma CP-I and CP-III within 0.078–15.0 nM. The results identify and address a number of challenges encountered with porphyrin assays such as photodegradation and interferences. To overcome interferences from ubiquitous porphyrins, a surrogate matrix was used to prepare calibration standards. Quality controls were prepared in plasma and surrogate matrix to ensure parallelism between surrogate matrix and plasma. Conclusion: A robust UHPLC–MS/MS assay was developed and validated for CP-I and CP-III in plasma, and is currently applied to clinical studies to confirm suitability of Coproporphyrins as a potential substitute for drug–drug interaction study.
- 11 May 2018
- Published by Taylor & Francis in Bioanalysis
- Vol. 10 (9) , 633-644
UHPLC–MS/MS Bioanalysis of Human Plasma Coproporphyrins as Potential Biomarkers for Organic Anion-Transporting Polypeptide-Mediated Drug Interactions
Aim: Coproporphyrins (CP-I and CP-III) have been identified as possible biomarkers to predict human hepatic organic anion-transporting polypeptides-mediated-drug-interactions for a new drug entering clinical development. Results: The method is applicable to quantify plasma CP-I and CP-III within 0.078–15.0 nM. The results identify and address a number of challenges encountered with porphyrin assays such as photodegradation and interferences. To overcome interferences from ubiquitous porphyrins, a surrogate matrix was used to prepare calibration standards. Quality controls were prepared in plasma and surrogate matrix to ensure parallelism between surrogate matrix and plasma. Conclusion: A robust UHPLC–MS/MS assay was developed and validated for CP-I and CP-III in plasma, and is currently applied to clinical studies to confirm suitability of Coproporphyrins as a potential substitute for drug–drug interaction study.